LEGISLATIVE GENERAL COUNSEL & Approved for Filing: E. Chelsea-McCarty & & 01-24-17 3:11 PM &

H.B. 110 1st Sub. (Buff)

Representative Paul Ray proposes the following substitute bill:

1	CONTROLLED SUBSTANCE AMENDMENTS
2	2017 GENERAL SESSION
3	STATE OF UTAH
4	Chief Sponsor: Paul Ray
5	Senate Sponsor: Allen M. Christensen
6	Cosponsor: Carol Spackman Moss
7	
8	LONG TITLE
9	General Description:
10	This bill modifies the Utah Controlled Substances Act.
11	Highlighted Provisions:
12	This bill:
13	adds the following to the list of controlled substances under Schedule I:
14	• 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide, also
15	known as U-47700 or "pink";
16	 Acetyl fentanyl: (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);
17	• Butyryl fentanyl: N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylbutyramide;
18	Furanyl fentanyl: and
19	N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide; and
20	adds the following to listed controlled substances:
21	• ADB-CHMINACA: N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]
22	-1-(cyclohexylmethyl)indazole-3-carboxamide;
23	• ADB-FUBINACA: (N-(1-amino-3,3-dimethyl-1oxobutan-2-yl)
24	-1-(4-fluorobenzyl)-1H-indazole-3-caboxamide); and



25	• FUB-AMB; methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)valinate.
26	Money Appropriated in this Bill:
27	None
28	Other Special Clauses:
29	This bill provides a special effective date.
30	Utah Code Sections Affected:
31	AMENDS:
32	58-37-4, as last amended by Laws of Utah 2015, Chapter 258
33	58-37-4.2, as last amended by Laws of Utah 2014, Chapter 23
3435	Be it enacted by the Legislature of the state of Utah:
36	Section 1. Section 58-37-4 is amended to read:
37	58-37-4. Schedules of controlled substances Schedules I through V Findings
38	required Specific substances included in schedules.
39	(1) There are established five schedules of controlled substances known as Schedules I,
40	II, III, IV, and V which consist of substances listed in this section.
41	(2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by
42	the official name, common or usual name, chemical name, or brand name designated:
43	(a) Schedule I:
44	(i) Unless specifically excepted or unless listed in another schedule, any of the
45	following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and
46	ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific
47	chemical designation:
48	(A) Acetyl-alpha-methylfentanyl
49	(N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
50	(B) Acetyl fentanyl: (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);
51	[(B)] <u>(C)</u> Acetylmethadol;
52	[(C)] <u>(D)</u> Allylprodine;
53	[(D)] (E) Alphacetylmethadol, except levo-alphacetylmethadol also known as
54	levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;
55	[(E)] <u>(F)</u> Alphameprodine;

```
56
              [<del>(F)</del>] (G) Alphamethadol;
              [(G)] (H) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]
57
58
      propionanilide: 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine):
59
              [(H)] (I) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-
60
      piperidinyl]-N-phenylpropanamide);
61
              [<del>(I)</del>] (J) Benzylpiperazine;
62
              [(J)] (K) Benzethidine;
63
              [<del>(K)</del>] (L) Betacetylmethadol;
64
              [(L)] (M) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
65
      piperidinyl]-N-phenylpropanamide);
              [(M)] (N) Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2-
66
67
      phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;
68
              [N] (O) Betameprodine;
69
              [\Theta] (P) Betamethadol;
70
              [<del>(P)</del>] (Q) Betaprodine;
              (R) Butyryl fentanyl: N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylbutyramide:
71
72
              [\Theta] (S) Clonitazene;
73
              [<del>(R)</del>] (T) Dextromoramide;
74
              [(S)] (U) Diampromide;
75
              [(T)] (V) Diethylthiambutene;
76
              [<del>(U)</del>] (W) Difenoxin;
77
              [(V)](X) Dimenoxadol;
78
              [(W)] (Y) Dimepheptanol;
79
              [(X)](Z) Dimethylthiambutene;
80
              [(Y)] (AA) Dioxaphetyl butyrate;
81
              [(Z)] (BB) Dipipanone;
82
              [(AA)] (CC) Ethylmethylthiambutene;
83
              [(BB)] (DD) Etonitazene;
84
              [<del>(CC)</del>] (EE) Etoxeridine;
85
              (FF) Furanyl fentanyl: N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]
      furan-2-carboxamide
86
```

```
1st Sub. (Buff) H.B. 110
```

```
87
                    [(DD)] (GG) Furethidine;
  88
                    [(EE)] (HH) Hydroxypethidine;
  89
                    [(FF)] (II) Ketobemidone;
  90
                    [(GG)] (JJ) Levomoramide;
  91
                    [(HH)] (KK) Levophenacylmorphan;
          \hat{S} \rightarrow [\hat{H} \rightarrow (LL)] Mitragynine (Kratom) and 7-hydroxymitragynine: (E)-2-[(2S,3S)-3-ethyl-8-
 91a
 91b
           methoxy-1, 2,3,4,6,7,12,12b-octahydroindolo[3,2-h] quinolizin-2-yl]-3-methoxyprop-2-enoic
 91c
          acid methyl ester; \leftarrow \hat{H} | \leftarrow \hat{S}
  92
                    [H] \hat{H} \rightarrow [LL] (MM) \leftarrow \hat{H} Morpheridine;
  93
                    [(JJ)] \hat{H} \rightarrow [(MM)] (NN) \leftarrow \hat{H} MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
  94
                    [(KK)] \hat{H} \rightarrow [(NN)] (OO) \leftarrow \hat{H} Noracymethadol;
  95
                    [(LL)] \hat{H} \rightarrow [(OO)] (PP) \leftarrow \hat{H} \text{ Norlevorphanol};
  96
                    [(MM)] \hat{H} \rightarrow [(PP)] (QQ) \leftarrow \hat{H} Normethadone;
  97
                    [(NN)] \hat{H} \rightarrow [(QQ)] (RR) \leftarrow \hat{H} Norpipanone;
  98
                    [(OO)] \hat{H} \rightarrow [(RR)] (SS) \leftarrow \hat{H} Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-
  99
          piperidinyl] propanamide;
 100
                    [PP] \hat{H} \rightarrow [SS] (TT) \leftarrow \hat{H} PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
 101
                    [(QQ)] \hat{H} \rightarrow [(TT)] (UU) \leftarrow \hat{H} Phenadoxone;
 102
                    [(RR)] \hat{H} \rightarrow [(UU)] (VV) \leftarrow \hat{H} Phenampromide;
 103
                    [(SS)] \hat{H} \rightarrow [(VV)] (WW) \leftarrow \hat{H} Phenomorphan;
 104
                    [(TT)] \hat{H} \rightarrow [(WW)] (XX) \leftarrow \hat{H} Phenoperidine;
 105
                    [(UU)] \hat{H} \rightarrow [(XX)] (YY) \leftarrow \hat{H} Piritramide;
                    [(VV)] \hat{H} \rightarrow [(YY)] (ZZ) \leftarrow \hat{H} Proheptazine;
 106
 107
                    [(WW)] \hat{H} \rightarrow [(ZZ)] (AAA) \leftarrow \hat{H} Properidine;
 108
                    [(XX)] \hat{H} \rightarrow [(AAA)] (BBB) \leftarrow \hat{H} Propiram;
 109
                    [(YY)] \hat{H} \rightarrow [(BBB)] (CCC) \leftarrow \hat{H} Racemoramide;
                    [(ZZ)] \hat{H} \rightarrow [(CCC)] (DDD) \leftarrow \hat{H} Thiofentanyl
 110
110a
          (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-
 111
          propanamide;
 112
                    [(AAA)] \hat{H} \rightarrow [(DDD)] (EEE) \leftarrow \hat{H} Tilidine;
 113
                    [(BBB)] \hat{H} \rightarrow [(EEE)] (FFF) \leftarrow \hat{H} Trimeperidine;
 114
                    [(CCC)] \hat{H} \rightarrow [(FFF)] (GGG) \leftarrow \hat{H} 3-methylfentanyl, including the optical and geometric
          isomers
114a
 115
          (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]- N-phenylpropanamide); [and]
 116
                    [(DDD)] \hat{H} \rightarrow [(GGG)] (HHH) \leftarrow \hat{H} 3-methylthiofentanyl
          (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide)[-]; and
 117
```

- 4 -

118	[(EEE)] Ĥ → [(HHH)] (III) ←Ĥ
118a	3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide
119	also known as U-47700.
120	(ii) Unless specifically excepted or unless listed in another schedule, any of the
121	following opium derivatives, their salts, isomers, and salts of isomers when the existence of the
122	salts, isomers, and salts of isomers is possible within the specific chemical designation:
123	(A) Acetorphine;
124	(B) Acetyldihydrocodeine;
125	(C) Benzylmorphine;
126	(D) Codeine methylbromide;
127	(E) Codeine-N-Oxide;
128	(F) Cyprenorphine;
129	(G) Desomorphine;
130	(H) Dihydromorphine;
131	(I) Drotebanol;
132	(J) Etorphine (except hydrochloride salt);
133	(K) Heroin;
134	(L) Hydromorphinol;
135	(M) Methyldesorphine;
136	(N) Methylhydromorphine;
137	(O) Morphine methylbromide;
138	(P) Morphine methylsulfonate;
139	(Q) Morphine-N-Oxide;
140	(R) Myrophine;
141	(S) Nicocodeine;
142	(T) Nicomorphine;
143	(U) Normorphine;
144	(V) Pholcodine; and
145	(W) Thebacon.
146	(iii) Unless specifically excepted or unless listed in another schedule, any material,
147	compound, mixture, or preparation which contains any quantity of the following hallucinogenic
148	substances, or which contains any of their salts, isomers, and salts of isomers when the

149 existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation; as used in this Subsection (2)(a)(iii) only, "isomer" includes the optical, position, 150 151 and geometric isomers: 152 (A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase; α -ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; α -ET; and AET; 153 154 (B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names: 155 4-bromo-2,5-dimethoxy-α-methylphenethylamine; 4-bromo-2,5-DMA; (C) 4-bromo-2.5-dimethoxyphenethylamine, some trade or other names: 156 157 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 2C-B, Nexus; (D) 2.5-dimethoxyamphetamine, some trade or other names: 158 159 2,5-dimethoxy-α-methylphenethylamine; 2,5-DMA; 160 (E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET; 161 (F) 4-methoxyamphetamine, some trade or other names: 4-methoxy-α-methylphenethylamine; paramethoxyamphetamine, PMA; 162 163 (G) 5-methoxy-3,4-methylenedioxyamphetamine: 164 (H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names: 4-methyl-2,5-dimethoxy-α-methylphenethylamine; "DOM"; and "STP"; 165 (I) 3.4-methylenedioxy amphetamine: 166 167 (J) 3.4-methylenedioxymethamphetamine (MDMA); (K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-168 169 alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA; 170 (L) N-hydroxy-3,4-methylenedioxyamphetamine, also known as 171 N-hvdroxy-alpha-methyl-3.4(methylenedioxy)phenethylamine, and N-hvdroxy MDA: (M) 3,4,5-trimethoxy amphetamine: 172 173 (N) Bufotenine, some trade and other names: 174 3-(β-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N, 175 N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine; (O) Diethyltryptamine, some trade and other names: N.N-Diethyltryptamine; DET: 176 177 (P) Dimethyltryptamine, some trade or other names: DMT; 178 (O) Ibogaine, some trade and other names: 179 7-Ethyl-6,6β,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2] azepino

180	[5,4-b] indole; Tabernanthe iboga;
181	(R) Lysergic acid diethylamide;
182	(S) Marijuana;
183	(T) Mescaline;
184	(U) Parahexyl, some trade or other names:
185	3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl;
186	(V) Peyote, meaning all parts of the plant presently classified botanically as
187	Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract from
188	any part of such plant, and every compound, manufacture, salts, derivative, mixture, or
189	preparation of such plant, its seeds or extracts (Interprets 21 USC 812(c), Schedule I(c) (12));
190	(W) N-ethyl-3-piperidyl benzilate;
191	(X) N-methyl-3-piperidyl benzilate;
192	(Y) Psilocybin;
193	(Z) Psilocyn;
194	(AA) Tetrahydrocannabinols, naturally contained in a plant of the genus Cannabis
195	(cannabis plant), as well as synthetic equivalents of the substances contained in the cannabis
196	plant, or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives,
197	and their isomers with similar chemical structure and pharmacological activity to those
198	substances contained in the plant, such as the following: $\Delta 1$ cis or trans tetrahydrocannabinol,
199	and their optical isomers $\Delta 6$ cis or trans tetrahydrocannabinol, and their optical isomers $\Delta 3,4$
200	cis or trans tetrahydrocannabinol, and its optical isomers, and since nomenclature of these
201	substances is not internationally standardized, compounds of these structures, regardless of
202	numerical designation of atomic positions covered;
203	(BB) Ethylamine analog of phencyclidine, some trade or other names:
204	N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine,
205	N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;
206	(CC) Pyrrolidine analog of phencyclidine, some trade or other names:
207	1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;
208	(DD) Thiophene analog of phencyclidine, some trade or other names:
209	1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP; and
210	(EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.

211	(iv) Unless specifically excepted or unless listed in another schedule, any material
212	compound, mixture, or preparation which contains any quantity of the following substances
213	having a depressant effect on the central nervous system, including its salts, isomers, and salts
214	of isomers when the existence of the salts, isomers, and salts of isomers is possible within the
215	specific chemical designation:
216	(A) Mecloqualone; and
217	(B) Methaqualone.
218	(v) Any material, compound, mixture, or preparation containing any quantity of the
219	following substances having a stimulant effect on the central nervous system, including their
220	salts, isomers, and salts of isomers:
221	(A) Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or
222	4,5-dihydro-5-phenyl-2-oxazolamine;
223	(B) Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone,
224	alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;
225	(C) Fenethylline;
226	(D) Methcathinone, some other names: 2-(methylamino)-propiophenone;
227	alpha-(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one;
228	alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone;
229	methylcathinone; AL-464; AL-422; AL-463 and UR1432, its salts, optical isomers, and salts of
230	optical isomers;
231	(E) (±)cis-4-methylaminorex ((±)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
232	(F) N-ethylamphetamine; and
233	(G) N,N-dimethylamphetamine, also known as
234	N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine.
235	(vi) Any material, compound, mixture, or preparation which contains any quantity of
236	the following substances, including their optical isomers, salts, and salts of isomers, subject to
237	temporary emergency scheduling:
238	(A) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and
239	(B) N-[1- (2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).
240	(vii) Unless specifically excepted or unless listed in another schedule, any material,
241	compound, mixture, or preparation which contains any quantity of gamma hydroxy butyrate

242

242	(gamma hydrobutyric acid), including its salts, isomers, and salts of isomers.
243	(b) Schedule II:
244	(i) Unless specifically excepted or unless listed in another schedule, any of the
245	following substances whether produced directly or indirectly by extraction from substances of
246	vegetable origin, or independently by means of chemical synthesis, or by a combination of
247	extraction and chemical synthesis:
248	(A) Opium and opiate, and any salt, compound, derivative, or preparation of opium or
249	opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone
250	and their respective salts, but including:
251	(I) Raw opium;
252	(II) Opium extracts;
253	(III) Opium fluid;
254	(IV) Powdered opium;
255	(V) Granulated opium;
256	(VI) Tincture of opium;
257	(VII) Codeine;
258	(VIII) Ethylmorphine;
259	(IX) Etorphine hydrochloride;
260	(X) Hydrocodone;
261	(XI) Hydromorphone;
262	(XII) Metopon;
263	(XIII) Morphine;
264	(XIV) Oxycodone;
265	(XV) Oxymorphone; and
266	(XVI) Thebaine;
267	(B) Any salt, compound, derivative, or preparation which is chemically equivalent or
268	identical with any of the substances referred to in Subsection (2)(b)(i)(A), except that these
269	substances may not include the isoquinoline alkaloids of opium;
270	(C) Opium poppy and poppy straw;
271	(D) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and
272	any salt, compound, derivative, or preparation which is chemically equivalent or identical with

302

303

(R) Pethidine (meperidine);

273 any of these substances, and includes cocaine and ecgonine, their salts, isomers, derivatives, 274 and salts of isomers and derivatives, whether derived from the coca plant or synthetically 275 produced, except the substances may not include decocainized coca leaves or extraction of coca 276 leaves, which extractions do not contain cocaine or ecgonine; and 277 (E) Concentrate of poppy straw, which means the crude extract of poppy straw in either 278 liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium poppy. 279 (ii) Unless specifically excepted or unless listed in another schedule, any of the 280 following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and 281 ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific 282 chemical designation, except dextrorphan and levopropoxyphene: 283 (A) Alfentanil; 284 (B) Alphaprodine; 285 (C) Anileridine; 286 (D) Bezitramide; (E) Bulk dextropropoxyphene (nondosage forms): 287 288 (F) Carfentanil; 289 (G) Dihydrocodeine; 290 (H) Diphenoxylate; 291 (I) Fentanyl; 292 (J) Isomethadone; 293 (K) Levo-alphacetylmethadol, some other names: levo-alpha-acetylmethadol, 294 levomethadyl acetate, or LAAM; 295 (L) Levomethorphan; 296 (M) Levorphanol; 297 (N) Metazocine; 298 (O) Methadone; 299 (P) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane; 300 (O) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic 301 acid;

(S) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;

304	(T) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
305	(U) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
306	(V) Phenazocine;
307	(W) Piminodine;
308	(X) Racemethorphan;
309	(Y) Racemorphan;
310	(Z) Remifentanil; and
311	(AA) Sufentanil.
312	(iii) Unless specifically excepted or unless listed in another schedule, any material,
313	compound, mixture, or preparation which contains any quantity of the following substances
314	having a stimulant effect on the central nervous system:
315	(A) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
316	(B) Methamphetamine, its salts, isomers, and salts of its isomers;
317	(C) Phenmetrazine and its salts; and
318	(D) Methylphenidate.
319	(iv) Unless specifically excepted or unless listed in another schedule, any material,
320	compound, mixture, or preparation which contains any quantity of the following substances
321	having a depressant effect on the central nervous system, including its salts, isomers, and salts
322	of isomers when the existence of the salts, isomers, and salts of isomers is possible within the
323	specific chemical designation:
324	(A) Amobarbital;
325	(B) Glutethimide;
326	(C) Pentobarbital;
327	(D) Phencyclidine;
328	(E) Phencyclidine immediate precursors: 1-phenylcyclohexylamine and
329	1-piperidinocyclohexanecarbonitrile (PCC); and
330	(F) Secobarbital.
331	(v) (A) Unless specifically excepted or unless listed in another schedule, any material,
332	compound, mixture, or preparation which contains any quantity of Phenylacetone.
333	(B) Some of these substances may be known by trade or other names:
334	phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl ketone.

(D) Chlorhexadol;

365

335	(vi) Nabilone, another name for nabilone:
336	(±)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,
337	6-dimethyl-9H-dibenzo[b,d]pyran-9-one.
338	(c) Schedule III:
339	(i) Unless specifically excepted or unless listed in another schedule, any material,
340	compound, mixture, or preparation which contains any quantity of the following substances
341	having a stimulant effect on the central nervous system, including its salts, isomers whether
342	optical, position, or geometric, and salts of the isomers when the existence of the salts, isomers
343	and salts of isomers is possible within the specific chemical designation:
344	(A) Those compounds, mixtures, or preparations in dosage unit form containing any
345	stimulant substances listed in Schedule II, which compounds, mixtures, or preparations were
346	listed on August 25, 1971, as excepted compounds under Section 1308.32 of Title 21 of the
347	Code of Federal Regulations, and any other drug of the quantitive composition shown in that
348	list for those drugs or which is the same except that it contains a lesser quantity of controlled
349	substances;
350	(B) Benzphetamine;
351	(C) Chlorphentermine;
352	(D) Clortermine; and
353	(E) Phendimetrazine.
354	(ii) Unless specifically excepted or unless listed in another schedule, any material,
355	compound, mixture, or preparation which contains any quantity of the following substances
356	having a depressant effect on the central nervous system:
357	(A) Any compound, mixture, or preparation containing amobarbital, secobarbital,
358	pentobarbital, or any salt of any of them, and one or more other active medicinal ingredients
359	which are not listed in any schedule;
360	(B) Any suppository dosage form containing amobarbital, secobarbital, or
361	pentobarbital, or any salt of any of these drugs which is approved by the Food and Drug
362	Administration for marketing only as a suppository;
363	(C) Any substance which contains any quantity of a derivative of barbituric acid or any
364	salt of any of them;

366	(E) Buprenorphine;
367	(F) Any drug product containing gamma hydroxybutyric acid, including its salts,
368	isomers, and salts of isomers, for which an application is approved under the federal Food,
369	Drug, and Cosmetic Act, Section 505;
370	(G) Ketamine, its salts, isomers, and salts of isomers, some other names for ketamine:
371	± -2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;
372	(H) Lysergic acid;
373	(I) Lysergic acid amide;
374	(J) Methyprylon;
375	(K) Sulfondiethylmethane;
376	(L) Sulfonethylmethane;
377	(M) Sulfonmethane; and
378	(N) Tiletamine and zolazepam or any of their salts, some trade or other names for a
379	tiletamine-zolazepam combination product: Telazol, some trade or other names for tiletamine:
380	2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade or other names for zolazepam:
381	4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one,
382	flupyrazapon.
383	(iii) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a
384	U.S. Food and Drug Administration approved drug product, some other names for dronabinol:
385	(6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or
386	(-)-delta-9-(trans)-tetrahydrocannabinol.
387	(iv) Nalorphine.
388	(v) Unless specifically excepted or unless listed in another schedule, any material,
389	compound, mixture, or preparation containing limited quantities of any of the following
390	narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid:
391	(A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
392	milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of
393	opium;
394	(B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
395	milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized
396	therapeutic amounts;

(J) Mesterolone;

(K) Methandienone;

426427

	15t 5ub. (Dull) 11.D. 110
397	(C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more
398	than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline
399	alkaloid of opium;
400	(D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more
401	than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in
402	recognized therapeutic amounts;
403	(E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90
404	milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized
405	therapeutic amounts;
406	(F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more
407	than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in
408	recognized therapeutic amounts;
409	(G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not
410	more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in
411	recognized therapeutic amounts; and
412	(H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with
413	one or more active, non-narcotic ingredients in recognized therapeutic amounts.
414	(vi) Unless specifically excepted or unless listed in another schedule, anabolic steroids
415	including any of the following or any isomer, ester, salt, or derivative of the following that
416	promotes muscle growth:
417	(A) Boldenone;
418	(B) Chlorotestosterone (4-chlortestosterone);
419	(C) Clostebol;
420	(D) Dehydrochlormethyltestosterone;
421	(E) Dihydrotestosterone (4-dihydrotestosterone);
422	(F) Drostanolone;
423	(G) Ethylestrenol;
424	(H) Fluoxymesterone;
425	(I) Formebulone (formebolone);

428	(L) Methandranone;
429	(M) Methandriol;
430	(N) Methandrostenolone;
431	(O) Methenolone;
432	(P) Methyltestosterone;
433	(Q) Mibolerone;
434	(R) Nandrolone;
435	(S) Norethandrolone;
436	(T) Oxandrolone;
437	(U) Oxymesterone;
438	(V) Oxymetholone;
439	(W) Stanolone;
440	(X) Stanozolol;
441	(Y) Testolactone;
442	(Z) Testosterone; and
443	(AA) Trenbolone.
444	(vii) Anabolic steroids expressly intended for administration through implants to cattle
445	or other nonhuman species, and approved by the Secretary of Health and Human Services for
446	use, may not be classified as a controlled substance.
447	(d) Schedule IV:
448	(i) Unless specifically excepted or unless listed in another schedule, any material,
449	compound, mixture, or preparation containing not more than 1 milligram of difenoxin and not
450	less than 25 micrograms of atropine sulfate per dosage unit, or any salts of any of them.
451	(ii) Unless specifically excepted or unless listed in another schedule, any material,
452	compound, mixture, or preparation which contains any quantity of the following substances,
453	including its salts, isomers, and salts of isomers when the existence of the salts, isomers, and
454	salts of isomers is possible within the specific chemical designation:
455	(A) Alprazolam;
456	(B) Barbital;
457	(C) Bromazepam;
458	(D) Butorphanol:

1st Sub. (Buff) H.B. 110

- 459 (E) Camazepam;
- 460 (F) Carisoprodol;
- 461 (G) Chloral betaine;
- 462 (H) Chloral hydrate;
- 463 (I) Chlordiazepoxide;
- 464 (J) Clobazam;
- 465 (K) Clonazepam;
- 466 (L) Clorazepate;
- 467 (M) Clotiazepam;
- 468 (N) Cloxazolam;
- 469 (O) Delorazepam;
- 470 (P) Diazepam;
- 471 (Q) Dichloralphenazone;
- 472 (R) Estazolam;
- 473 (S) Ethchlorvynol;
- 474 (T) Ethinamate;
- 475 (U) Ethyl loflazepate;
- 476 (V) Fludiazepam;
- 477 (W) Flunitrazepam;
- 478 (X) Flurazepam;
- 479 (Y) Halazepam;
- 480 (Z) Haloxazolam;
- 481 (AA) Ketazolam;
- 482 (BB) Loprazolam;
- 483 (CC) Lorazepam;
- 484 (DD) Lormetazepam;
- 485 (EE) Mebutamate;
- 486 (FF) Medazepam;
- 487 (GG) Meprobamate;
- 488 (HH) Methohexital;
- 489 (II) Methylphenobarbital (mephobarbital);

490	(JJ) Midazolam;
491	(KK) Nimetazepam;
492	(LL) Nitrazepam;
493	(MM) Nordiazepam;
494	(NN) Oxazepam;
495	(OO) Oxazolam;
496	(PP) Paraldehyde;
497	(QQ) Pentazocine;
498	(RR) Petrichloral;
499	(SS) Phenobarbital;
500	(TT) Pinazepam;
501	(UU) Prazepam;
502	(VV) Quazepam;
503	(WW) Temazepam;
504	(XX) Tetrazepam;
505	(YY) Triazolam;
506	(ZZ) Zaleplon; and
507	(AAA) Zolpidem.
508	(iii) Any material, compound, mixture, or preparation of fenfluramine which contains
509	any quantity of the following substances, including its salts, isomers whether optical, position,
510	or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of
511	isomers is possible.
512	(iv) Unless specifically excepted or unless listed in another schedule, any material,
513	compound, mixture, or preparation which contains any quantity of the following substances
514	having a stimulant effect on the central nervous system, including its salts, isomers whether
515	optical, position, or geometric isomers, and salts of the isomers when the existence of the salts,
516	isomers, and salts of isomers is possible within the specific chemical designation:
517	(A) Cathine ((+)-norpseudoephedrine);
518	(B) Diethylpropion;
519	(C) Fencamfamine;
520	(D) Fenproprex;

1st Sub. (Buff) H.B. 110

521	(E) Mazindol;
522	(F) Mefenorex;
523	(G) Modafinil;
524	(H) Pemoline, including organometallic complexes and chelates thereof;
525	(I) Phentermine;
526	(J) Pipradrol;
527	(K) Sibutramine; and
528	(L) SPA ((-)-1-dimethylamino-1,2-diphenylethane).
529	(v) Unless specifically excepted or unless listed in another schedule, any material,
530	compound, mixture, or preparation which contains any quantity of dextropropoxyphene
531	(alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane), including its salts.
532	(e) Schedule V: Any compound, mixture, or preparation containing any of the
533	following limited quantities of narcotic drugs, or their salts calculated as the free anhydrous
534	base or alkaloid, which includes one or more non-narcotic active medicinal ingredients in
535	sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal
536	qualities other than those possessed by the narcotic drug alone:
537	(i) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
538	(ii) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100
539	grams;
540	(iii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100
541	grams;
542	(iv) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of
543	atropine sulfate per dosage unit;
544	(v) not more than 100 milligrams of opium per 100 milliliters or per 100 grams;
545	(vi) not more than 0.5 milligram of difenoxin and not less than 25 micrograms of
546	atropine sulfate per dosage unit;
547	(vii) unless specifically exempted or excluded or unless listed in another schedule, any
548	material, compound, mixture, or preparation which contains Pyrovalerone having a stimulant
549	effect on the central nervous system, including its salts, isomers, and salts of isomers; and
550	(viii) all forms of Tramadol.
551	Section 2. Section 58-37-4.2 is amended to read:

```
552
               58-37-4.2. Listed controlled substances.
553
               The following substances, their analogs, homologs, and synthetic equivalents are listed
554
       controlled substances:
555
               (1) AB-001;
556
               (2) AB-PINACA;
557
       N-[1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole-3-carboxamide;
558
               (3) AB-FUBINACA; N-[1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)
559
       methyl]-1H-indazole-3-carboxamide;
560
               (4) ADB-CHMINACA: N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-
561
       (cyclohexylmethyl)indazole-3-carboxamide;
562
               (5) ADB-FUBINACA: (N-(1-amino-3,3-dimethyl-1oxobutan-2-yl)-1-
563
       (4-fluorobenzyl)-1H-indazole-3-caboxamide);
564
               [<del>(4)</del>] (6) AKB48;
565
               [(5)] (7) alpha-Pyrrolidinovalerophenone (alpha-PVP);
566
               [(6)] (8) AM-694; 1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl)methanone;
567
               [<del>(7)</del>] (9) AM-1248;
568
               [<del>(8)</del>] (10) AM-2201; 1-(5-fluoropentyl)-3-(1-naphthoyl)indole;
569
               [<del>(9)</del>] (11) AM-2233;
570
               [<del>(10)</del>] (12) AM-679;
571
               [<del>(11)</del>] (13) A796,260;
572
               [(12)] (14) Butylone;
573
               [<del>(13)</del>] (15) CP 47,497 and its C6, C8, and C9 homologs;
574
       2-[(1R,3S)-3-hydroxycyclohexyl] -5-(2-methyloctan-2-yl)phenol;
575
               [(14)] (16) Diisopropyltryptamine (DiPT);
               [<del>(15)</del>] (17) Ethylone;
576
577
               [\frac{(16)}{(18)}] (18) Ethylphenidate;
               [(17)] (19) Fluoroisocathinone;
578
579
               [(18)] (20) Fluoromethamphetamine;
580
               [<del>(19)</del>] (21) Fluoromethcathinone;
581
               (22) FUB-AMB; methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)valinate;
582
               [<del>(20)</del>] (23) HU-210;
```

```
583
       (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
584
       -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
585
                [<del>(21)</del>] (24) HU-211; Dexanabinol, (6aS, 10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-
586
       methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
587
                [<del>(22)</del>] (25) JWH-015; (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenyl-methanone;
588
                [<del>(23)</del>] (26) JWH-018; Naphthalen-1-yl-(pentylindol-3-yl)methanone {also known as
589
       1-Pentyl-3-(1-naphthoyl)indole};
590
               [<del>(24)</del>] (27) JWH-019; 1-hexyl-3-(1-naphthoyl)indole;
591
               [(25)] (28) JWH-073; Naphthalen-1-yl(1-butylindol-3-yl)methanone {also known as
592
       1-Butyl-3-(1-naphthoyl)indole};
                [<del>(26)</del>] (29) JWH-081; 4-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone:
593
594
                [<del>(27)</del>] (30) JWH-122; CAS#619294-47-2; (1-Pentyl-3-(4-methyl-1-naphthoyl)indole);
595
                [<del>(28)</del>] (31) JWH-200; 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl)indole;
                [<del>(29)</del>] (32) JWH-203; 1-pentyl-3-(2-chlorophenylacetyl)indole;
596
597
               [<del>(30)</del>] (33) JWH-210; 4-ethyl-1-naphthalenyl(1-pentyl-1H-indol-3-yl)-methanone;
598
               [(31)] (34) JWH-250; 1-pentyl-3-(2-methoxyphenylacetyl)indole;
599
               [<del>(32)</del>] (35) JWH-251; 2-(2-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone;
600
                [<del>(33)</del>] (36) JWH-398: 1-pentyl-3-(4-chloro-1-naphthoyl)indole:
601
               [<del>(34)</del>] (37) MAM-2201;
602
                [<del>(35)</del>] (38) MAM-2201;
603
       (1-(5-fluoropentyl)-1H-indol-3-yl)(4-ethyl-1-naphthalenyl)-methanone;
604
                [(36)] (39) Methoxetamine;
605
               [(37)] (40) Naphyrone;
606
               [<del>(38)</del>] (41) PB-22; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester;
607
               [(39)] (42) Pentedrone;
608
               \left[\frac{(40)}{(43)}\right] (43) Pentylone;
609
               [<del>(41)</del>] (44) RCS-4; 1-pentyl-3-(4-methoxybenzoyl)indole;
610
               [<del>(42)</del>] (45) RCS-8; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole {also
611
       known as BTW-8 and SR-18};
612
                [<del>(43)</del>] (46) STS-135;
613
                [<del>(44)</del>] (47) UR-144;
```

```
614
                [<del>(45)</del>] (48) UR-144 N-(5-chloropentyl) analog;
615
                [<del>(46)</del>] (49) XLR11;
616
                [(47)] (50) 2C-C;
617
                [(48)] (51) 2C-D;
618
                [(49)] (52) 2C-E;
                [<del>(50)</del>] (53) 2C-H;
619
                [<del>(51)</del>] (54) 2C-I;
620
621
                [(52)] (55) 2C-N;
622
                [<del>(53)</del>] <u>(56)</u> 2C-P;
623
                [<del>(54)</del>] (57) 2C-T-2;
                [<del>(55)</del>] <u>(</u>58) 2C-T-4;
624
625
                [<del>(56)</del>] (59) 2NE1;
626
                [<del>(57)</del>] (60) 25I-NBOMe;
627
                [(58)] (61) 2,5-Dimethoxy-4-chloroamphetamine (DOC);
628
                [(59)] (62) 4-methylmethcathinone {also known as mephedrone};
629
                [(60)] (63) 3,4-methylenedioxypyrovalerone {also known as MDPV};
630
                [(61)] (64) 3,4-Methylenedioxymethcathinone {also known as methylone};
631
                [<del>(62)</del>] (65) 4-methoxymethcathinone;
632
                [<del>(63)</del>] (66) 4-Methyl-alpha-pyrrolidinopropiophenone;
633
                [<del>(64)</del>] (67) 4-Methylethcathinone;
634
                [<del>(65)</del>] (68) 5F-AKB48;
635
        1-(5-flouropentyl)-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3- carboxamide;
636
                [(66)] (69) 5-fluoro-PB-22; 1-(5-fluoropentyl)-1H-indole-3-carboxylic acid
637
        8-quinolinyl ester;
638
                [<del>(67)</del>] (70) 5-Iodo-2-aminoindane (5-IAI);
639
                [<del>(68)</del>] (71) 5-MeO-DALT;
640
                [<del>(69)</del>] (72) 25B-NBOMe; 2-(r-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)
641
        methyl]ethanamine;
642
                [<del>(70)</del>] (73) 25C-NBOMe; 2-(4Chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)
643
        methyl]ethanamine; and
644
                [<del>(71)</del>] (74) 25H-NBOMe;
```

645	2-(2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine.
646	Section 3. Effective date.
647	If approved by two-thirds of all the members elected to each house, this bill takes effect
648	upon approval by the governor, or the day following the constitutional time limit of Utah
649	Constitution, Article VII, Section 8, without the governor's signature, or in the case of a veto,
650	the date of veto override.

1st Sub. (Buff) H.B. 110